ADIA Nutrition Inc. to Host Webinar on HSCT for MS and Autoimmune Conditions with HSCT Warriors

Rhea-AI Summary

ADIA Nutrition (OTCQB: ADIA) will host a live webinar on Thursday, November 20, 2025 at 6:30 PM EST on Hematopoietic Stem Cell Transplantation (HSCT) for Multiple Sclerosis and other autoimmune conditions.

Dr. Evan Thomas, MD, PhD, medical director of Adia Med HSCT Program, will discuss the science, patient outcomes, and Adia Med’s physician-led approach. Registration is available via Zoom and interested parties can contact CEO Larry Powalisz for more information or partnership inquiries.

Winter Park, Florida--(Newsfile Corp. - November 19, 2025) - ADIA Nutrition, Inc. (OTCQB: ADIA) invites all shareholders, supporters, and potential investors to join a live webinar tomorrow, Thursday, November 20, 2025, at 6:30 PM EST, hosted by HSCT Warriors.

HSCT Warriors

To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/274553_hsct_warriors_logo.jpg

The webinar will focus on Hematopoietic Stem Cell Transplantation (HSCT) for Multiple Sclerosis (MS) and other autoimmune conditions, treatments.

Guest Speaker:
Dr. Evan Thomas, MD, PhD
Medical Director, Adia Med
Director, Adia Med HSCT Program

Dr. Thomas will discuss the science, patient outcomes, and Adia Med's physician-led, compliant approach to bringing this life-changing therapy to U.S. patients.

Webinar Details:
Date: Thursday, November 20, 2025
Time: 6:30 PM EST
Register Now: https://us02web.zoom.us/webinar/register/4017629068254/WN_S9OsJomHQ5aKcWQivjZL4g

"I was diagnosed with MS over five years ago. I had brain fog and had paralysis on my left side. I was told by my neurologist that I would be in a wheelchair within three to five years. I had HSCT in Mexico, and it gave me my life back. No wheelchair for me!," said Larry Powalisz, CEO of ADIA Nutrition.

"Now, we're proud to bring this same proven therapy to patients right here in the U.S. safely, legally, and under full physician oversight. This webinar is your chance to hear directly from our medical director."

For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.

Clinic owners and healthcare practitioners interested in licensing the Adia Med name or integrating Adia's regenerative therapies into their practice are encouraged to reach out directly. Strategic partnerships are welcomed as part of Adia's continued mission to expand access to advanced stem cell solutions.

About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, AdiaLabs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.

Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.

Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition

Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/274553

FAQ

When is ADIA (OTCQB: ADIA) hosting the HSCT webinar and how do I register?

The webinar is on Thursday, November 20, 2025 at 6:30 PM EST; register via the provided Zoom registration link.

Who will present for ADIA’s HSCT webinar and what topics will Dr. Evan Thomas cover?

Dr. Evan Thomas, MD, PhD, will present and discuss the science of HSCT, patient outcomes, and Adia Med’s physician-led, compliant approach.

How can ADIA shareholders or investors get more information about the November 20, 2025 HSCT webinar?

Shareholders can register on Zoom and contact CEO Larry Powalisz at ceo@adiamed.com or 321-788-0850 for inquiries.

Will ADIA (ADIA) discuss U.S. availability of HSCT during the webinar?

Yes; the webinar description says it will cover Adia Med’s approach to bringing HSCT to U.S. patients under physician oversight.

Can clinic owners license the Adia Med name after the ADIA HSCT webinar on November 20, 2025?

Clinic owners and healthcare practitioners are encouraged to contact the company to discuss licensing and integrating Adia’s regenerative therapies.

What patient perspective is included in ADIA’s HSCT webinar announcement?

The announcement includes a CEO patient testimony describing personal improvement after receiving HSCT.